Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Iker Ausejo‐Mauleon
Observed names:
I Ausejo,
I Ausejo-Mauleon,
Iker Ausejo,
Iker Ausejo Mauleón,
Iker Ausejo-Mauleon,
Iker Ausejo-Mauleón
show all 6
Institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada,
Universidad de Navarra
Observed institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada,
Universidad de Navarra
ORCID:
0000-0002-0590-6579
Observed ORCID:
0000-0002-0590-6579
OpenAlex ID:
A5023916916
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
2023
·
Iker Ausejo-Mauleon
, Sara Labiano
, et al.
·
Cancer Cell
·
120
PDF
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
2021
·
Montserrat Puigdelloses
, Marc Garcia-Moure
, et al.
·
Journal for ImmunoTherapy of Cancer
·
53
Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
2022
·
Virginia Laspidea
, Montserrat Puigdelloses
, et al.
·
JCI Insight
·
24
Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
2021
·
Naiara Martinez-Velez
, Virginia Laspidea
, et al.
·
Molecular Cancer Therapeutics
·
22
PDF
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
2024
·
Daniel de la Nava
, Iker Ausejo-Mauleon
, et al.
·
Neuro-Oncology
·
16
PDF
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models
2024
·
Iker Ausejo-Mauleon
, Naiara Martinez-Velez
, et al.
·
JCI Insight
·
12
PDF
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas
2025
·
Sara Labiano
, Javier Marco-Sanz
, et al.
·
Cell Reports Medicine
·
10
Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry
2023
·
Iker Ausejo-Mauleon
, Sara Labiano
, et al.
·
STAR Protocols
·
8
Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma
2022
·
Guillermo Herrador-Cañete
, Marta Zalacain
, et al.
·
Molecular Therapy — Oncolytics
·
8
PDF
The rise of TIM‐3: A promising immune target in diffuse midline gliomas
2024
·
Iker Ausejo‐Mauleon
, Sara Nuin
, et al.
·
Clinical and Translational Medicine
·
7
PDF
P17.14.b Phase I Trial of Dnx-2401 Oncolytic Adenovirus Combined With a Short Course of Dose-dense Temozolomide for Recurrent Glioblastoma
2023
·
J Gallego Perez-Larraya
, M García-Moure
, et al.
·
Neuro-Oncology
·
5
PDF
P17.15.a Thank Phase I Trial of Dnx-2440 Oncolytic Adenovirus in Patients With First or Second Recurrence of Glioblastoma: Preliminary Results
2023
·
J Gallego Perez-Larraya
, D de la Nava
, et al.
·
Neuro-Oncology
·
4
PDF
Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters
2025
·
Daniel Palacios-Alonso
, Miriam Bazan-Peregrino
, et al.
·
Human Gene Therapy
·
1
Dipg-13. Tim-3 Targeted Aptamer in Combination With Loco-regional Radiotherapy Improves Survival by Modulating the Immune Infiltration in Diffuse Midline Glioma Models
2024
·
Iker Ausejo-Mauleon
, Daniel de la Nava
, et al.
·
Neuro-Oncology
·
1
PDF
Dipg-04. Tumor Cell-intrinsic Tim-3 Promotes Diffuse Intrinsic Pontine Glioma Tumorigenesis
2023
·
Iker Ausejo-Mauleon
, Virginia Laspidea
, et al.
·
Neuro-Oncology
·
1
PDF
DIPG-22. Modifying the tumor microenvironment with a TIM-3 monoclonal antibody as a therapeutic strategy for DIPGs
2022
·
Iker Ausejo-Mauleon
, Sara Labiano
, et al.
·
Neuro-Oncology
·
1
745 Oncolytic adenovirus expressing 4-1BBL demonstrates a significant increase of survival in Diffuse Midline Glioma models
2021
·
Virginia Laspidea
, Sara Labiano
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
ID #1041 Evaluation of the antitumor effect of paxalisib in combination with oncolytic virotherapy for Diffuse Midline Glioma
2026
·
Daniel Palacios-Alonso
, Irati Hervás-Corpión
, et al.
·
Neuro-Oncology Pediatrics
Replication-competent adenoviral platform for in situ production of immunotherapeutic RNA aptamers targeting 4-1BB
2026
·
Antonio Carlos Tallon-Cobos
, Virginia Laspidea
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
Ctni-47. Phase I Trial of Single Intratumoral Injection of Dnx-2440 Oncolytic Adenovirus in Recurrent Glioblastoma Patients
2025
·
Jaime Gallego Perez de Larraya
, Noelia Casares
, et al.
·
Neuro-Oncology
PDF
Js07.5.a Therapeutic Tim-3 Inhibition Supports Neurological Function Post-tumor Clearance in Dmg Preclinical Models
2025
·
S Morales-Sánchez
, I Ausejo-Mauleon
, et al.
·
Neuro-Oncology
PDF
P06.11.a Conventional Type 1 Dendritic Cells Enhance Neuroprotection in Pediatric Brain Tumor Radiotherapy
2025
·
J Marco-Sanz
, A Lacalle
, et al.
·
Neuro-Oncology
PDF
DMG-17. The combination of Delta-24-RGD and TIM-3 blockade enhances oncolytic virotherapy in diffuse midline glioma.
2025
·
Sara Nuin
, Iker Ausejo-Mauleón
, et al.
·
Neuro-Oncology Pediatrics
DMG-21. Improving oncolytic virotherapy by blocking CD47- SIRPα axis with single-domain antibodies in diffuse midline gliomas
2025
·
Daniel Palacios-Alonso
, Sara Nuin
, et al.
·
Neuro-Oncology Pediatrics
DMG-13. Cognitive and motor effects of TIM-3 blockade in diffuse midline glioma murine models
2025
·
Sandra Morales-Sánchez
, Iker Ausejo-Mauleon
, et al.
·
Neuro-Oncology Pediatrics
Show more works
View as search
Works count:
47
Citation count:
294
H-index:
8
I10-index:
7
Year
Topic
Type